Bukwang Pharmaceutical Launches Comprehensive Cold Medicine 'Tasenol Cold'

Bukwang Pharmaceutical's comprehensive cold medicine 'Tasenol Cold Capsule'
[Photo by Bukwang Pharmaceutical]

[Asia Economy Reporter Chunhee Lee] Bukwang Pharmaceutical announced on the 23rd that it has launched the comprehensive cold medicine product "Tasenol Cold Capsule" in the representative antipyretic analgesic 'Tasenol' lineup.

Tasenol has actively responded to the shortage of antipyretic analgesics and cold medicines that began around the time of COVID-19 vaccination, increasing production and supply to establish itself as one of the leading antipyretic analgesic products. Subsequently, it has positioned itself with the slogan "Korea's Antipyretic Analgesic" through online advertising, recently expanding its product lineup. Following Tasenol 500mg with the single ingredient acetaminophen, Tasenol IR 8-hour 650mg, and Tasenol 160mg for children, the launch of the comprehensive cold medicine Tasenol Cold has broadened the product range from antipyretic analgesics to cold medicines. Bukwang Pharmaceutical explained, "With increases not only in the general drug market but also in prescriptions, we expect it to become a blockbuster item this year."

Tasenol Cold Capsule, as a comprehensive cold medicine, contains six ingredients: acetaminophen, an effective antipyretic analgesic for chills, fever, headache, and muscle pain; dextromethorphan hydrobromide hydrate and DL-methyl ephedrine hydrochloride for cough relief; guaifenesin for phlegm relief; chlorpheniramine maleate for alleviating cold symptoms; and caffeine to reduce drowsiness after taking the medicine.

A representative from Bukwang Pharmaceutical stated, "To establish ourselves as Korea's household medicine brand, we will continue brand promotion targeting pharmacists and consumers as we do now," adding, "We plan to steadily expand the brand lineup and nurture it into a blockbuster brand this year."